Author:
El-Khatib Ahmed H.,Radbruch Helena,Trog Sabrina,Neumann Boris,Paul Friedemann,Koch Arend,Linscheid Michael W.,Jakubowski Norbert,Schellenberger Eyk
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Clinical Neurology,Neurology
Reference12 articles.
1. FDA. FDA Drug Safety Communication: FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs; review to continue [online]. Available at: fda.gov/Drugs/DrugSafety/ucm559007.htm. Accessed September 22, 2017.
2. EMA. EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans [online]. Available at: ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Gadolinium-containing_contrast_agents/human_referral_prac_000056.jsp. Accessed September 22, 2017.
3. Interpreting signal-intensity ratios without visible T1 hyperintensities in clinical gadolinium retention studies
4. Erratum to: signal intensity at unenhanced T1-weighted magnetic resonance in the globus pallidus and dentate nucleus after serial administrations of a macrocyclic gadolinium-based contrast agent in children;Espagnet;Pediatr Radiol,2017
5. Signal Increase on Unenhanced T1-Weighted Images in the Rat Brain After Repeated, Extended Doses of Gadolinium-Based Contrast Agents
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献